Systemic Prednisone Should Generally Be Avoided for Severe Pediatric Eczema
Systemic corticosteroids, including prednisone, are strongly discouraged for the treatment of severe eczema in children due to significant risks of rebound flares, growth suppression, and other serious adverse effects that outweigh short-term benefits. 1
Why Systemic Steroids Are Not Recommended for Eczema
The evidence is clear and consistent across multiple high-quality guidelines:
The 2014 American Academy of Dermatology guidelines explicitly state that systemic steroids should generally be avoided in both adults and children with atopic dermatitis because potential short-term and long-term adverse effects largely outweigh benefits 1
Rebound flaring is a commonly observed phenomenon upon discontinuation, with one study showing premature discontinuation due to significant rebound flaring in the prednisolone group 1
Only 1 of 27 patients (4%) achieved durable remission with prednisolone in a controlled trial, demonstrating poor long-term efficacy 1
Critical Adverse Effects in Children
Pediatric patients face unique and serious risks:
- Growth suppression and decreased linear growth while on medication 1, 2
- Weight gain, growth retardation, decreased bone density, and Cushingoid features develop in approximately 20% of children receiving prolonged steroid therapy 3
- Adrenal suppression
- Emotional lability
- Glucose intolerance
- Hypertension
When Systemic Steroids Might Be Considered (Rarely)
If systemic corticosteroids are used at all in pediatric eczema, they should only be considered as a short-term bridge therapy while initiating other systemic immunomodulatory agents or phototherapy in severe, rapidly progressive, or debilitating cases 1. The International Eczema Council reached consensus that systemic corticosteroids can be used rarely under certain circumstances, though most respondents agreed they should never be used in children (though formal consensus was not reached on that specific statement) 4.
Dosing If Absolutely Necessary
If prednisone must be used as a bridge therapy, the FDA-approved dosing range is 5-60 mg per day, individualized based on disease severity 2. For pediatric dosing by weight:
- 0.5-1.0 mg/kg/day is the general range used in practice 1
- Administer as a single morning dose prior to 9 AM to minimize HPA axis suppression 2
- A taper schedule is required to decrease risk of adrenal suppression 1
- Treatment should be time-limited (typically days to 1-2 weeks maximum as bridge therapy)
Important Caveat on Dosing Calculations
Research shows that dosing at 2 mg/kg/day versus 60 mg/m²/day is NOT equivalent for patients <30 kg, with weight-based dosing resulting in significantly lower doses 5. This discrepancy matters when extrapolating from other conditions, though again, systemic steroids should be avoided for eczema regardless of calculation method.
Preferred Treatment Approach
Modern management of severe pediatric eczema should center on:
- Topical corticosteroids as first-line therapy (potent or moderate potency for severe disease) 6, 7
- Topical calcineurin inhibitors for steroid-sparing maintenance 6
- Biologics (IL-4/IL-13 inhibitors like dupilumab) for moderate-to-severe disease 8
- JAK inhibitors (oral or topical) for refractory cases 8
- Phototherapy in appropriate candidates
Topical corticosteroids remain indispensable and safe when used with appropriate potency, duration, and vehicle selection 8, 6. The emergence of biologics and JAK inhibitors has substantially altered the therapeutic landscape, making systemic corticosteroids even less justifiable 8.
Critical Monitoring If Systemic Steroids Are Used
Children on systemic steroids require:
- Blood pressure monitoring
- Growth velocity measurement
- Bone density evaluation consideration
- HPA axis suppression testing if prolonged use
- Never abrupt withdrawal 2
The evidence overwhelmingly supports avoiding systemic prednisone for pediatric eczema and instead utilizing topical therapies, biologics, or JAK inhibitors for disease control.